Vericel Corp (VCEL)
47.83
-0.05
(-0.10%)
USD |
NASDAQ |
May 03, 16:00
47.81
-0.02
(-0.04%)
After-Hours: 20:00
Vericel Cash from Financing (Quarterly): 1.307M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.307M |
| September 30, 2023 | 1.009M |
| June 30, 2023 | 1.195M |
| March 31, 2023 | 0.107M |
| December 31, 2022 | 0.605M |
| September 30, 2022 | -0.312M |
| June 30, 2022 | 0.249M |
| March 31, 2022 | 0.503M |
| December 31, 2021 | 1.341M |
| September 30, 2021 | 1.787M |
| June 30, 2021 | 3.781M |
| March 31, 2021 | 2.262M |
| December 31, 2020 | 4.454M |
| September 30, 2020 | 0.791M |
| June 30, 2020 | 0.89M |
| March 31, 2020 | 0.306M |
| December 31, 2019 | 1.527M |
| September 30, 2019 | 1.683M |
| June 30, 2019 | 1.068M |
| March 31, 2019 | 0.982M |
| December 31, 2018 | -17.17M |
| September 30, 2018 | 1.909M |
| June 30, 2018 | 71.43M |
| March 31, 2018 | 2.694M |
| December 31, 2017 | 11.28M |
| Date | Value |
|---|---|
| September 30, 2017 | 7.185M |
| June 30, 2017 | 0.051M |
| March 31, 2017 | 0.061M |
| December 31, 2016 | 23.51M |
| September 30, 2016 | 3.56M |
| June 30, 2016 | 2.485M |
| March 31, 2016 | 0.152M |
| December 31, 2015 | -0.009M |
| September 30, 2015 | -0.001M |
| June 30, 2015 | -0.005M |
| March 31, 2015 | -0.009M |
| December 31, 2014 | -0.304M |
| September 30, 2014 | 41.32M |
| June 30, 2014 | 3.46M |
| March 31, 2014 | 5.451M |
| December 31, 2013 | 1.586M |
| September 30, 2013 | 10.46M |
| June 30, 2013 | -0.01M |
| March 31, 2013 | 2.367M |
| December 31, 2012 | -0.009M |
| September 30, 2012 | 0.16M |
| June 30, 2012 | -0.113M |
| March 31, 2012 | 37.89M |
| December 31, 2011 | -0.045M |
| September 30, 2011 | -0.043M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.312M
Minimum
Sep 2022
4.454M
Maximum
Dec 2020
1.292M
Average
1.068M
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | -11.92M |
| Arbutus Biopharma Corp | 3.807M |
| Chimerix Inc | 0.062M |
| Karyopharm Therapeutics Inc | 0.264M |
| Y-mAbs Therapeutics Inc | 0.10M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 10.09M |
| Cash from Investing (Quarterly) | -8.088M |
| Free Cash Flow | 7.798M |
| Free Cash Flow Per Share (Quarterly) | 0.0471 |
| Free Cash Flow to Equity (Quarterly) | 2.251M |
| Free Cash Flow to Firm (Quarterly) | 2.251M |
| Free Cash Flow Yield | 0.34% |